Rodent models of pulmonary hypertension: Harmonisation with the world health organisation's categorisation of human PH

International Journal of Clinical Practice

Volumn 65, Issue SUPPL. 172, 2011, Pages 15-34

  Ryan, J ^a   Bloch, K ^b   Archer, Stephen L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALVASCULIN; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POTASSIUM CHANNEL KV1.5; SEMAXANIB; SEROTONIN TRANSPORTER; SHORT HAIRPIN RNA; SILDENAFIL; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NFAT; ANTIHYPERTENSIVE AGENT;

AIRWAY REMODELING; APOPTOSIS; ARTERY INTIMA PROLIFERATION; CELL PROLIFERATION; CIGARETTE SMOKING; DISEASE MODEL; DISEASE SEVERITY; FAWN HOODED HYPERTENSIVE RAT; GAMMAHERPESVIRINAE; HEART DISEASE; HEART EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; HYPOXIA; INCIDENCE; LIPID DIET; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG DISEASE; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG RESECTION; LUNG VASOCONSTRICTION; LUNG WEDGE PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; RNA INTERFERENCE; RODENT; SCHISTOSOMIASIS; STACHYBOTRYS CHARTARUM; SURVIVAL RATE; WORLD HEALTH ORGANIZATION; ANIMAL; CAUSE OF DEATH; COMPARATIVE STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MOUSE; NEEDLE BIOPSY; RAT; RISK ASSESSMENT; SPECIES DIFFERENCE; SURVIVAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOPSY, NEEDLE; CAUSE OF DEATH; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MICE; PNEUMONECTOMY; RATS; RISK ASSESSMENT; RODENTIA; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 79960090535     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02710.x     Document Type: Review

References (108)

1. Simonneau G, Robbins IM, Beghetti M, et al., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S43-54.
2. Archer SL, Weir EK, Wilkins MR,. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-66.
3. Lewis GD, Shah R, Shahzad K, et al., Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-62. (Pubitemid 47511419)
4. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD,. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339-48. (Pubitemid 39647608)
5. McMurtry MS, Bonnet S, Michelakis ED, Haromy A, Archer SL,. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007; 293: L933-40. (Pubitemid 47572241)
6. Chesney CF, Allen JR,. Animal model: pulmonary hypertension, cor pulmonale and endocardial fibroelastosis in monocrotaline-intoxicated nonhuman primates. Am J Pathol 1973; 70: 489-92.
7. Lee SL, Fanburg BL,. Serotonin uptake by bovine pulmonary artery endothelial cells in culture I. Characterization. Am J Physiol 1986; 250: C761-5.
8. Villamor E, Le Cras TD, Horan MP, Halbower AC, Tuder RM, Abman SH,. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol 1997; 272: L1013-20.
9. Starling MB, Neutze JM, Elliott RL,. Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI2). Prostaglandins Med 1979; 3: 105-17. (Pubitemid 10225535)
10. Stenmark KR, Fasules J, Hyde DM, et al., Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol 1987; 62: 821-30. (Pubitemid 17066650)
11. Grover TR, Parker TA, Markham NE, Abman SH,. rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289: L315-21. (Pubitemid 41008915)
12. Archer S, Rich S,. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000; 102: 2781-91.
13. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M,. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-87.
14. Humbert M, Sitbon O, Chaouat A, et al., Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.
15. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S,. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-9. (Pubitemid 47074013)
16. Naeije R,. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 20-2. (Pubitemid 40562958)
17. Pengo V, Lensing AW, Prins MH, et al., Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-64.
18. Sweiss NJ, Hushaw L, Thenappan T, et al., Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2010; 12: 8-18.
19. Herve P, Launay JM, Scrobohaci ML, et al., Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
20. Christman BW, McPherson CD, Newman JH, et al., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5.
21. Steudel W, Ichinose F, Huang PL, et al., Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 1997; 81: 34-41. (Pubitemid 27272980)
22. Stewart DJ, Levy RD, Cernacek P, Langleben D,. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
23. Krick S, Platoshyn O, Sweeney M, Kim H, Yuan JX,. Activation of K+ channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C970-9.
24. Ekhterae D, Platoshyn O, Krick S, Yu Y, McDaniel SS, Yuan JX,. Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 281: C157-65.
25. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M,. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005; 112: 423-31. (Pubitemid 41022085)
26. Morrell NW, Yang X, Upton PD, et al., Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104: 790-5. (Pubitemid 32762677)
27. Zhang S, Fantozzi I, Tigno DD, et al., Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-54. (Pubitemid 37022876)
28. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL,. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 292: L872-8. (Pubitemid 46608233)
29. Marcos E, Adnot S, Pham MH, et al., Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168: 487-93. (Pubitemid 37046880)
30. Perros F, Montani D, Dorfmuller P, et al., Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-8. (Pubitemid 351919196)
31. Archer SL, Marsboom G, Kim GH, et al., Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010; 121: 2661-71.
32. Reeve HL, Michelakis E, Nelson DP, Weir EK, Archer SL,. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol 2001; 90: 2249-56. (Pubitemid 32467419)
33. Yuan JX, Aldinger AM, Juhaszova M, et al., Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-6. (Pubitemid 28462800)
34. McMurtry MS, Archer SL, Altieri DC, et al., Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005; 115: 1479-91. (Pubitemid 40814657)
35. Bonnet S, Rochefort G, Sutendra G, et al., The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104: 11418-23. (Pubitemid 47175155)
36. McMurtry MS, Bonnet S, Wu X, et al., Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004; 95: 830-40. (Pubitemid 39390586)
37. Michelakis ED, McMurtry MS, Wu XC, et al., Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002; 105: 244-50. (Pubitemid 34084326)
38. Bonnet S, Michelakis ED, Porter CJ, et al., An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006; 113: 2630-41. (Pubitemid 43948012)
39. Young KA, Ivester C, West J, Carr M, Rodman DM,. BMP signaling controls PASMC KV channel expression in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2006; 290: L841-8. (Pubitemid 43725045)
40. Guignabert C, Izikki M, Tu LI, et al., Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006; 98: 1323-30. (Pubitemid 43948088)
41. Guignabert C, Tu L, Izikki M, et al., Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009; 23: 4135-47.
42. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL,. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010; 299: L401-12.
43. Thibault HB, Kurtz B, Raher MJ, et al., Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging 2010; 3: 157-63.
44. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY,. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 2002; 283: H364-71. (Pubitemid 34705359)
45. Bras G, Jelliffe DB, Stuart KL,. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol 1954; 57: 285-300.
46. Lalich JJ, Merkow L,. Pulmonary arteritis produced in rat by feeding Crotalaria spectabilis. Lab Invest 1961; 10: 744-50.
47. Hayashi Y, Lalich JJ,. Renal and pulmonary alterations induced in rats by a single injection of monocrotaline. Proc Soc Exp Biol Med 1967; 124: 392-6.
48. Kay JM, Harris P, Heath D,. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 1967; 22: 176-9.
49. Buermans HP, Redout EM, Schiel AE, et al., Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. Physiol Genomics 2005; 21: 314-23. (Pubitemid 40898491)
50. Rosenberg HC, Rabinovitch M,. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988; 255: H1484-91.
51. Archer S, Gebhard R, Levine A, Prigge W, Weir E,. Exacerbation of monocrotaline pulmonary hypertension by a high fat diet: association with increased production lung levels of activated oxygen species. J Vasc Med Biol 1990; 2: 125-35.
52. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD,. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 1997; 151: 1019-25. (Pubitemid 27424311)
53. White RJ, Meoli DF, Swarthout RF, et al., Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L583-90. (Pubitemid 47358820)
54. Tschopp B, Weiss HJ,. Decreased ATP, ADP and serotonin in young platelets of fawn-hooded rats with storage pool disease. Thromb Diath Haemorrh 1974; 32: 670-7.
55. Tobach E, DeSantis JL, Zucker MB,. Platelet storage pool disease in hybrid rats. F1 fawn-hooded rats derived from crosses with their putative ancestors (Rattus norvegicus). J Hered 1984; 75: 15-8. (Pubitemid 14196997)
56. Kentera D, Susic D, Veljkovic V, Tucakovic G, Koko V,. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 1988; 54: 110-4.
57. Nagaoka T, Gebb SA, Karoor V, et al., Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 2006; 100: 996-1002. (Pubitemid 43671557)
58. Le Cras TD, Kim DH, Gebb S, et al., Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat. Am J Physiol 1999; 277: L709-18. (Pubitemid 29522636)
59. Le Cras TD, Kim DH, Markham NE, Abman AS,. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am J Physiol Lung Cell Mol Physiol 2000; 279: L283-91.
60. Sato K, Webb S, Tucker A, et al., Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992; 145: 793-7.
61. Nagaoka T, Muramatsu M, Sato K, McMurtry I, Oka M, Fukuchi Y,. Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 2001; 127: 53-60. (Pubitemid 32622147)
62. Ashmore RC, Rodman DM, Sato K, et al., Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. Am J Physiol 1991; 260: H1929-34.
63. Gonzalez AM, Smith AP, Emery CJ, Higenbottam TW,. The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence. Am J Respir Cell Mol Biol 1998; 19: 245-9. (Pubitemid 128354187)
64. Cowley AW Jr, Liang M, Roman RJ, Greene AS, Jacob HJ,. Consomic rat model systems for physiological genomics. Acta Physiol Scand 2004; 181: 585-92. (Pubitemid 39078858)
65. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al., Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-38. (Pubitemid 32141434)
66. Oka M, Homma N, Taraseviciene-Stewart L, et al., Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923-9. (Pubitemid 46555698)
67. Abe K, Toba M, Alzoubi A, et al., Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010; 121: 2747-54.
68. Du L, Sullivan CC, Chu D, et al., Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500-9. (Pubitemid 36159885)
69. Kugathasan L, Dutly AE, Zhao YD, et al., Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension. Chest 2005; 128: 633S-42S. (Pubitemid 43054177)
70. Chu D, Sullivan CC, Du L, et al., A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. Ann Thorac Surg 2004; 77: 449-56. discussion 56-7. (Pubitemid 38186487)
71. Eddahibi S, Humbert M, Fadel E, et al., Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-50. (Pubitemid 32995372)
72. MacLean MR, Deuchar GA, Hicks MN, et al., Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004; 109: 2150-5. (Pubitemid 38620226)
73. Lane KB, Machado RD, Pauciulo MW, et al., Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-4.
74. Newman JH, Wheeler L, Lane KB, et al., Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319-24. (Pubitemid 32703234)
75. Liu D, Wang J, Kinzel B, et al., Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 2007; 110: 1502-10. (Pubitemid 47443965)
76. West J, Fagan K, Steudel W, et al., Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94: 1109-14. (Pubitemid 38579706)
77. Hong KH, Lee YJ, Lee E, et al., Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008; 118: 722-30.
78. Beppu H, Ichinose F, Kawai N, et al., BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1241-7. (Pubitemid 39507203)
79. West J, Harral J, Lane K, et al., Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008; 295: L744-55.
80. Beppu H, Kawabata M, Hamamoto T, et al., BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 2000; 221: 249-58. (Pubitemid 30253588)
81. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY,. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005; 112: 553-62. (Pubitemid 41060796)
82. Long L, MacLean MR, Jeffery TK, et al., Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006; 98: 818-27.
83. Beppu H, Lei H, Bloch KD, Li E,. Generation of a floxed allele of the mouse BMP type II receptor gene. Genesis 2005; 41: 133-7.
84. Beppu H, Malhotra R, Beppu Y, Lepore JJ, Parmacek MS, Bloch KD,. BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol 2009; 331: 167-75.
85. Robbins IM, Newman JH, Johnson RF, et al., Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136: 31-6.
86. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N,. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 2009; 50 (Suppl): S178-82.
87. Hansmann G, Wagner RA, Schellong S, et al., Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007; 115: 1275-84. (Pubitemid 46594772)
88. Spiekerkoetter E, Alvira CM, Kim YM, et al., Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am J Physiol Lung Cell Mol Physiol 2008; 294: L276-89. (Pubitemid 351253364)
89. Crosby A, Jones FM, Southwood M, et al., Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010; 181: 279-88.
90. Ochiai E, Kamei K, Watanabe A, et al., Inhalation of Stachybotrys chartarum causes pulmonary arterial hypertension in mice. Int J Exp Pathol 2008; 89: 201-8. (Pubitemid 351661566)
91. Zimmer HG, Gerdes AM, Lortet S, Mall G,. Changes in heart function and cardiac cell size in rats with chronic myocardial infarction. J Mol Cell Cardiol 1990; 22: 1231-43.
92. Dai ZK, Tan MS, Chai CY, et al., Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol 2004; 37: 249-56.
93. Dai ZK, Tan MS, Chai CY, et al., Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Exp Biol Med (Maywood) 2006; 231: 942-7.
94. Rabinovitch M, Fisher K, Gamble W, Reid L, Treves S,. Thallium-201: quantitation of right ventricular hypertrophy in chronically hypoxic rats. Radiology 1979; 130: 223-5. (Pubitemid 9087339)
95. McMurtry IF, Petrun MD, Reeves JT,. Lungs from chronically hypoxic rats have decreased pressor response to acute hypoxia. Am J Physiol 1978; 235: H104-9. (Pubitemid 9181141)
96. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M,. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002; 122: 326S-34S. (Pubitemid 36043023)
97. Stenmark KR, Fagan KA, Frid MG,. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-91. (Pubitemid 44498302)
98. Reid LM,. The third grover conference on the pulmonary circulation. The control of cellular proliferation in the pulmonary circulation. Am Rev Respir Dis 1989; 140: 1490-3. (Pubitemid 19276249)
99. Hampl V, Archer SL, Nelson DP, Weir EK,. Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993; 75: 1748-57. (Pubitemid 23318227)
100. Durmowicz AG, Hofmeister S, Kadyraliev TK, Aldashev AA, Stenmark KR,. Functional and structural adaptation of the yak pulmonary circulation to residence at high altitude. J Appl Physiol 1993; 74: 2276-85. (Pubitemid 23157050)
101. Belknap JK, Orton EC, Ensley B, Tucker A, Stenmark KR,. Hypoxia increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Am J Respir Cell Mol Biol 1997; 16: 366-71. (Pubitemid 127497461)
102. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF,. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1013-32.
103. Li H, Elton TS, Chen YF, Oparil S,. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994; 266: L553-60.
104. Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, McMurtry IF,. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 2002; 282: L703-12. (Pubitemid 34665585)
105. Ivy DD, McMurtry IF, Colvin K, et al., Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 2005; 111: 2988-96. (Pubitemid 40814193)
106. Wang T, Han SX, Zhang SF, et al., Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res 2010; 11: 36.
107. Moser KM, Cantor JP, Olman M, et al., Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation 1991; 83: 1371-9.
108. Bauer NR, Moore TM, McMurtry IF,. Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 2007; 293: L580-2. (Pubitemid 47358819)